FDA may not retain all of the new positions it added in recent years to meet its needs under the generic drug user fee program.
As part of the massive effort to expand the Office of Generic Drugs and other functions within the agency to improve reviews of ANDAs and other generic drug submissions and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?